SCHEMBL4791069

SCHEMBL4791069

O=C(O)CC1CCN(C(=O)NC2CCC(Nc3ccccn3)CC2)Cc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.47
ITGB3 P05106 8/20 0.45
ITGAV P06756 8/20 0.45
ITGA2B P08514 6/20 0.45
ITGB5 P18084 6/20 0.45
POLB P06746 1/20 0.43
ITGB1 P05556 1/20 0.41
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
DRD4 P21917 1/20 0.40
CYP46A1 Q9Y6A2 2/20 0.40
BTK Q06187 1/20 0.40
EPHX2 P34913 2/20 0.39
CYP3A4 P08684 1/20 0.39
KCNH2 Q12809 1/20 0.39
CACNA1C Q13936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791067 1.00 NOS2 (0.47) NOS2ITGB3ITGAVITGA2BITGB5
SCHEMBL4791386 0.83 ITGB3 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4762284 0.82 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4761797 0.81 ITGB3 (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760017 0.81 ITGB3 (0.54) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4715004 0.79 ITGB3 (0.44) NOS2ITGB3ITGAVITGA2BITGB5
SCHEMBL4761828 0.79 DPP4 (0.50) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4790512 0.78 GRIN2B (0.53) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760226 0.77 ITGB3 (0.42) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL4760436 0.77 ITGB3 (0.51) ITGB3ITGAVITGA2BITGB5ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP claimed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US claimed
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed